Cryopreserved mesenchymal stromal cell treatment is safe and feasible for severe dilated ischemic cardiomyopathy

SZE-PIAW CHIN1, ALFRED C. POEY2, CHEE-YIN WONG3, SAU-KONG CHANG2, WILLIAM TEH2, TEDDRIC JON MOHR2 & SOON-KENG CHEONG1

1International Medical University, Kuala Lumpur, Malaysia, 2Penang Adventist Hospital, Penang, Malaysia, and 3Cytopeutics, Selangor, Malaysia

Abstract

Background aims. Bone marrow (BM) mesenchymal stromal cells (MSC) represent a novel therapy for severe heart failure with extensive myocardial scarring, especially when performed concurrently with conventional revascularization. However, stem cells are difficult to transport in culture media without risk of contamination, infection and reduced viability. We tested the feasibility and safety of off-site MSC culture and expansion with freeze-controlled cryopreservation and subsequent rapid thawing of cells immediately prior to implantation to treat severe dilated ischemic cardiomyopathy. Methods. We recruited three consecutive patients with end-stage ischemic heart failure with evidence of full-thickness myocardial scarring. MSC was isolated from 20 mL BM aspiration, expanded and cryopreserved using 10% dimethyl sulfoxide (DMSO). Cells were transported in a cryoshipper. Patients underwent concurrent coronary artery bypass graft (CABG) with intramyocardial MSC injection. Results. The cell viability after thawing exceeded 90% for all samples. The supernatant was free from bacterial and fungal growth. All patients underwent the procedure safely. There were no arrhythmias noted. There was significant improvement in cardiac function and volume, resolution of scarring and increased wall thickness for all patients on cardiac magnetic resonance imaging at 6 months compared with baseline. The magnitude of improvement was more than was expected with CABG alone. Patients remained well at 1 year. Conclusions. Rate-controlled freezing with 10% DMSO is a safe, feasible and practical method of cryopreserving MSC for cell storage and transportation without risk of contamination or cell death. Direct MSC injection may be beneficial as an adjunct to cardiac revascularization.

Key Words: cryopreservation, heart failure, ischemic cardiomyopathy, mesenchymal stromal cell

Introduction

Cell therapy is a promising new option for patients with myocardial infarction and severe intractable heart failure (1–3). Mesenchymal stromal cells (MSC) that are found in the bone marrow (BM) have been shown to benefit ischemic cardiomyopathy by several mechanisms, including cardiac cell regeneration, scar tissue resolution, formation of supportive collagen matrix, angiogenesis and paracrine action, that hasten recovery from inflammation (4–9). In one study, intracoronary infusion of MSC for patients who had suffered acute myocardial infarction apparently improved left ventricular function, restored movement of the infarcted regions and reduced scar tissues and left ventricular volumes (7).

Among the limitations of clinical trials is the difficulty in transporting stem cells out of the cell culture facility to operating theatres and hospitals. Commonly in clinical trials, the cells are kept in culture flasks in constant-controlled incubators until required, when they are then removed from the flasks and resuspended in vials or syringes to be transported to the adjacent operating theatre. While such a workflow is convenient for combined clinical research institutions, it would not be practical for other hospitals without on-site or nearby cell-culture facilities, as not only could the cells become infected or contaminated during transportation but changes in temperature, humidity and oxygen content will also harm the cells. For the same reason, once the stem cells have been removed from the incubator and culture flasks, the procedure or decision to proceed cannot be changed or delayed. Yet delays and postponements in operations are inevitable. Therefore the current method of providing and transporting stem cells is not practical for wider applications.

One practical solution around this problem is to cryopreserve the stem cells upon attaining the numbers required and transport the cells in this state to
the operation theatre and thaw only when required. Cryopreserved stem cells have been in clinical practice for some time now, especially hematopoietic cells for the treatment of leukemia and lymphoma (10–13). However, these cryopreserved cells are normally infused intravenously so the small amounts of cryopreservative used, such as dimethyl sulfoxide (DMSO), are insignificant compared with the intravascular volume. There are a few articles that have reported that cryopreserved BM-derived MSC can retain its expansion and differentiation properties (14–17). However, there is scarce literature on the use of cryopreserved BM-derived MSC for clinical treatment of cardiomyopathy either as transcorynary infusion or the preferred method of direct intramyocardial injection. Therefore providing proof that DMSO-added cryopreserved MSC is safe and feasible for direct intramyocardial injection for patients with heart failure can serve as the first step towards establishing the ‘missing link’ between clinical stem cell trials conducted in university hospitals to translational therapy where the cells produced from one site may be transported safely for use at a remote site.

In this pilot study, we tested the safety and feasibility of using cryopreserved MSC for the treatment of patients with severe intractable heart failure undergoing a concurrent cardiac bypass operation with direct intramyocardial injection.

**Methods**

**Patient selection**

Patients were recruited from a combined cardiology–cardiothoracic clinic (Table I). The inclusion criteria were age between 55 and 75 years old, symptomatic heart failure [New York Heart Association (NYHA) functional classes II–IV] despite optimal medications, previous myocardial infarction (MI) between 3 and 24 months previously, documented left ventricular dysfunction by echocardiography, documented fixed defects or irreversible myocardial scarring on magnetic resonance imaging (MRI) or positron emission tomography (PET) scans, and regarded as high-risk outweighing benefit of revascularization by at least two qualified physicians. The contraindications included any contraindication to BM biopsy, angioplasty or cardiac bypass operation, any acute or chronic intercurrent illnesses such as infections, severe renal failure (serum creatinine greater than 200 mM), liver failure (transaminase greater than 2 × ULN) and any past or current cancers. All patients signed an extensive informed consent form and gave permission for their data to be published. The study had the approval of the local hospital medical and ethics board.

**BM aspiration and MSC culture**

We obtained 20 mL BM aspirate (BMA) from each patient using a 14-G Jamshidi needle inserted in the superior posterior iliac crest under local anesthesia. The BMA was collected into pre-heparinized tubes and transferred immediately to the cell culture facility to be processed. Processing time from collection ranged from 4 to 12 h.

BMA was diluted 1:1 with phosphate-buffered saline (PBS) (Gibco, Grand Island, NY, USA) and layered over an equal volume of Ficoll–Paque Premium 1.073 solution (Amersham Biosciences, Uppsala, Sweden). The sample was centrifuged at 400 g for 40 min. Mononuclear cells (MNC) were recovered from the gradient interface and washed with PBS before being resuspended in Dulbecco’s modified Eagle’s medium containing low glucose (DMEM-LG; Gibco) supplemented with 10% autologous serum, 100 U/mL penicillin, 100 µg/mL streptomycin, 250 ng/mL amphotericin B and 2 mM GlutaMAX (Gibco). The cultures were maintained at 37°C in a humidified atmosphere of 5% CO₂ and 95% air.

After 3 days, non-adherent cells were discarded. Fresh culture medium was replaced every few days until cells reached confluence. The adherent cells were harvested after briefly incubating with TrypLE Select (Gibco) and resuspended at low density, thus expanding the population of MSC. MSC were confirmed by the presence and absence of several surface adhesions molecules and their ability to differentiate into adipocytes, chondrocytes and osteocytes, as described previously (18,19).

**MSC cryopreservation and final preparation**

When the required number of cells was reached, MSC were harvested and cryopreserved in 90% autologous plasma and 10% DMSO (Cryoserv, Lake Forest, IL, USA). The cells were frozen gradually using a rate-controlled freezer (Thermo Fisher Scientific, Marietta, OH, USA) to −90°C, whereupon they were transferred into vapor phase liquid nitrogen storage. Small volumes of cell culture media that had been used for MSC culture were sent for bacterial and fungal tests.

One day before MSC injection, cryopreserved MSC were transferred to the hospital in a cryoshipper. At the operating theatre, the cells were thawed in a 37°C warm water bath, washed once and then resuspended using sterile 0.9% normal saline solution. The MSC suspension was transferred into a 10 mL luer-lock syringe with a 27-G needle, ready for injection. The duration from cryopreservation to day of surgery was 5–16 days. The viability of the cells in the final suspension was more than 90% in all three cases. The duration from cell resuspension to injection was 1–3 h (Figure 1).
Intramyocardial injection

Before the operation, patients underwent cardiac perfusion imaging to confirm the presence and extent of scarred or non-viable areas. This was confirmed visually at open heart surgery. Following completion of coronary grafting, the aortic cross clamp was released and blood allowed to fill the ventricle. The MSC suspension was then injected around the scar tissue in a circumference (20). Typically 15–20 sites spaced 1–2 cm apart were injected using a 27-G needle. At each site, 0.5–1.0 mL MSC suspension was injected and light pressure applied after withdrawal of needle.

Follow-up

Patients remained in hospital for 1–2 weeks. They were monitored in the cardiothoracic intensive care unit by telemetry during the first 48 h for any ventricular arrhythmias. At the end of the hospital stay, patients had an echocardiography to exclude pericardial effusions. They were required to return for follow-up at 6 weeks, 3 months, 6 months and 12 months. Echocardiography to evaluate left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), interventricular septal thickness at diastole (IVSd) and regional wall motion index (RWMI) was performed at each visit and compared with baseline values. Cardiac MRI with gadolinium delay enhancement was performed at baseline and 6 months to look for scarring and non-viable areas.

Results

Case 1

A 61-year-old man with three previous MI, stroke with residual hemiparesis and slurred speech, diabetes (HbA1c 7.5) and hypertension presented with severe heart failure (NYHA IV). His LVEF was 20.8% by echocardiography and 26.0% by MRI. MRI further revealed extensive non-viable scarred areas at the anterior, septal and apical segments, with a large antero-apical aneurysm. Thirteen milliliters of BMA were obtained under local anesthetic, which yielded about 20 million MNC. After 4 weeks, we obtained 28 million MSC. The cells were delivered to the hospital 5 days later. The patient underwent quadruple coronary artery bypass grafting (CABG). Atherectomy was also performed to the left anterior descending (LAD) artery. MSC was injected directly into the myocardium...
around the extensive scar tissue. Twenty injections of 0.5 mL each were performed. There were no arrhythmias documented throughout the cardiac monitoring. The patient made an uneventful recovery and at 6 weeks reported improvement in functional class and symptoms (NYHA I–II) and LVEF to 55.0% by echocardiography. Repeat echocardiography findings at 6 months showed LVEF of 53.0% by echocardiography and 37.0% by MRI. MRI also showed no more scarring or aneurysm. In addition there was an increase of muscle thickness in all segments of the left heart, including the previously scarred areas (Figure 1).

Case 2
A 63-year-old man with two previous MI, diabetes (HbA1c 8.2%), hypertension and moderate renal failure (serum creatinine 180 mM) presented with heart failure (NYHA III) and angina pectoris (CCS II). His LVEF was 37.0% by echocardiography and 28% by MRI. MRI further revealed extensive non-viable scarred areas at the inferior, posterior and apical segments. Twenty milliliters of BMA were obtained under local anesthetic, which yielded about 32 million MNC. After 4 weeks of cell culture, we obtained 21 million MSC. The cells were delivered to the hospital 16 days later. The patient underwent quadruple CABG. MSC was injected directly into the myocardium around the extensive scar tissue. Twenty injections of 0.5 mL each were performed. There were no arrhythmias documented throughout the cardiac monitoring. The patient was discharged after 2 weeks but was re-admitted 1 month later with hemorrhagic gastritis, most probably caused by anti-platelet therapy. Despite the complication, there was improvement in functional class and symptoms (NYHA II) and LVEF to 52.4% by echocardiography. Repeat echocardiography findings at 6 months showed further LVEF improvement to 50.0%, 49.0% by MRI.

Case 3
A 64-year-old man presented with three previous MI between 1994 and 2008, dyslipidemia, diabetes (HbA1c 7.2%) and hypertension with severe heart failure (NYHA IV). His LVEF was 32.0% by echocardiography and 37.0% by MRI. MRI further revealed extensive non-viable scarred areas at the anterior, septal, lateral, inferior and posterior segments, with a large antero-apical aneurysm. Twenty-seven milliliters of BMA were obtained under local anesthetic, which yielded about 34 million MNC. After 4 weeks, we obtained 35 million MSC. The cells were delivered to the hospital 5 days later. The patient underwent quadruple CABG. MSC was injected directly into the myocardium around the extensive scar tissue at the anterior, septal, lateral, inferior and posterior segments only. Twenty injections of 0.5 mL each were performed. There were no arrhythmias documented throughout the cardiac monitoring. The patient made an uneventful recovery and at 6 weeks reported improvement in functional class and symptoms (NYHA I–II) and LVEF to 53.0% by echocardiography and 37.0% by MRI. MRI also showed reduced scarring at the anterior and apical segments but no reduction of scarring in the areas not previously injected.

Discussion
The ability to store stem cells in a dormant, stable and sterile state for a period of time prior to transplantation is important for practical clinical applications,
Cryopreserved MSC for heart failure

35
effects and also potentially cause hypersensitivity reactions (27–29). There are also reports of acute encephalopathy, yet guidelines for their use in stem cell transplantation do not exist. In 2004, the European Group for Blood and Transplantation (EBMT) carried out a questionnaire survey on DMSO toxicity in autologous stem cell transplantation (30). Out of 34 000 transplants, at least 470 cases of toxicity were reported and almost half of the cases were cardiovascular in nature. Moreover, it was reported that the incidence of toxicity was significantly lower when cells were washed before transplantation. Thus, it is recommended to wash DMSO-containing cryopreserved cells before transplantation. For our method of direct intramyocardial injection, the cells need to be washed quickly and resuspended in sterile normal saline solution. Typically, for a 2-mL cryovial containing up to 10 million MSC, we add 10% DMSO (0.2 mL) and 90% autologous plasma (1.8 mL) for cryopreservation. At the end of this final cell preparation, after a single wash and resuspension, the DMSO content is less than 1% in a 10-mL syringe containing up to 30 million MSC (Figure 2).

As all three case studies illustrate, intramyocardial injection of stem cells is feasible and safe. They also illustrate significant improvement in heart contractility and function, with resolution of symptoms and myocardial scarring. The magnitude of improvement in heart contractility by an average of 20% points, which exceeds that of either CABG or angioplasty revascularization procedures alone,
was reported consistently as 10% after 6 months. We used two methods of LVEF measurement, and MRI is regarded as superior and is currently the gold standard. With MRI, an LVEF improvement of 5% is regarded as significant recovery, whereas our patients demonstrated 10–20% point improvement. Furthermore, there was normalization of the left ventricular end diastolic and systolic diameters, which indicates reduction in dilatation and scarring. These results are similar to other published literature using either BM stem cells or more specifically MSC (1–9). All the more remarkable is that all three patients were deemed previously to have end-stage heart failure and be unlikely to benefit from revascularization strategy alone because of non-viable scars, and all remained well at up to 12 months follow-up.

The three cases in this pilot study have demonstrated the safety and feasibility of direct intramyocardial injection of cryopreserved MSC. Cryopreserving MSC in a rate-controlled manner does not lead to significant cell death and is an important practical consideration for storage, transportation and quality assurance. The cryopreserved MSC may be efficacious for the treatment of severe intractable heart failure.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References


